"Glucagon-Like Peptide 1" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A peptide of 36 or 37 amino acids that is derived from PROGLUCAGON and mainly produced by the INTESTINAL L CELLS. GLP-1(1-37 or 1-36) is further N-terminally truncated resulting in GLP-1(7-37) or GLP-1-(7-36) which can be amidated. These GLP-1 peptides are known to enhance glucose-dependent INSULIN release, suppress GLUCAGON release and gastric emptying, lower BLOOD GLUCOSE, and reduce food intake.
Below are MeSH descriptors whose meaning is more general than "Glucagon-Like Peptide 1".
Below are MeSH descriptors whose meaning is more specific than "Glucagon-Like Peptide 1".
This graph shows the total number of publications written about "Glucagon-Like Peptide 1" by people in Harvard Catalyst Profiles by year, and whether "Glucagon-Like Peptide 1" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1991 | 0 | 2 | 2 |
| 1992 | 0 | 4 | 4 |
| 1993 | 0 | 3 | 3 |
| 1994 | 0 | 1 | 1 |
| 1995 | 0 | 2 | 2 |
| 1996 | 0 | 3 | 3 |
| 1997 | 0 | 1 | 1 |
| 1998 | 0 | 5 | 5 |
| 1999 | 0 | 6 | 6 |
| 2000 | 0 | 4 | 4 |
| 2001 | 0 | 6 | 6 |
| 2002 | 0 | 5 | 5 |
| 2003 | 0 | 4 | 4 |
| 2004 | 0 | 1 | 1 |
| 2005 | 1 | 1 | 2 |
| 2006 | 1 | 1 | 2 |
| 2007 | 1 | 3 | 4 |
| 2008 | 4 | 1 | 5 |
| 2009 | 3 | 3 | 6 |
| 2010 | 4 | 6 | 10 |
| 2011 | 10 | 8 | 18 |
| 2012 | 7 | 2 | 9 |
| 2013 | 10 | 5 | 15 |
| 2014 | 5 | 5 | 10 |
| 2015 | 4 | 4 | 8 |
| 2016 | 9 | 4 | 13 |
| 2017 | 7 | 5 | 12 |
| 2018 | 1 | 3 | 4 |
| 2019 | 4 | 7 | 11 |
| 2020 | 5 | 7 | 12 |
| 2021 | 0 | 2 | 2 |
Below are the most recent publications written about "Glucagon-Like Peptide 1" by people in Profiles.
-
Switching to iGlarLixi versus continuation of a daily or weekly glucagon-like peptide-1 receptor agonist (GLP-1 RA) in insufficiently controlled type 2 diabetes: A LixiLan-G trial subgroup analysis by HbA1c and GLP-1 RA use at screening. Diabetes Obes Metab. 2021 06; 23(6):1331-1341.
-
A microbial metabolite remodels the gut-liver axis following bariatric surgery. Cell Host Microbe. 2021 03 10; 29(3):408-424.e7.
-
Effect of the glucagon-like peptide-1 analogue liraglutide versus placebo treatment on circulating proglucagon-derived peptides that mediate improvements in body weight, insulin secretion and action: A randomized controlled trial. Diabetes Obes Metab. 2021 02; 23(2):489-498.
-
Risk of amputation with canagliflozin across categories of age and cardiovascular risk in three US nationwide databases: cohort study. BMJ. 2020 08 25; 370:m2812.
-
Bariatric surgery reveals a gut-restricted TGR5 agonist with anti-diabetic effects. Nat Chem Biol. 2021 01; 17(1):20-29.
-
Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design. Am Heart J. 2020 11; 229:61-69.
-
Effect of Sleeve Gastrectomy on Ghrelin, GLP-1, PYY, and GIP Gut Hormones: A Systematic Review and Meta-analysis. Ann Surg. 2020 07; 272(1):72-80.
-
Pleiotropic effects of antidiabetic agents on renal and cardiovascular outcomes: a meta-analysis of randomized controlled trials. Int Urol Nephrol. 2020 Sep; 52(9):1733-1745.
-
Hydrocarbon-Stitched Peptide Agonists of Glucagon-Like Peptide-1 Receptor. ACS Chem Biol. 2020 06 19; 15(6):1340-1348.
-
Effects of Glucagon-like Peptide-1 on the Reproductive Axis in Healthy Men. J Clin Endocrinol Metab. 2020 04 01; 105(4).